PRX-03140
PRX-03140 is a partial agonist (18% relative to 5-HT[1]) of the 5-HT4 receptor that is being developed by EPIX Pharmaceuticals for Alzheimer's disease.[2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H27N3O3S |
Molar mass | 377.501 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Shen F, Smith JA, Chang R, et al. (2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515.
- Shen, F (August 2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.